- Home
- PKE vs ATYR Comparison
PKE vs ATYR Comparison
Compare PKE & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PKE
- ATYR
- Stock Information
- Founded
- PKE 1954
- ATYR 2005
- Country
- PKE United States
- ATYR United States
- Employees
- PKE N/A
- ATYR N/A
- Industry
- PKE Military/Government/Technical
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PKE Industrials
- ATYR Health Care
- Exchange
- PKE Nasdaq
- ATYR Nasdaq
- Market Cap
- PKE 260.2M
- ATYR 451.3M
- IPO Year
- PKE N/A
- ATYR 2015
- Fundamental
- Price
- PKE $17.39
- ATYR $5.76
- Analyst Decision
- PKE
- ATYR Strong Buy
- Analyst Count
- PKE 0
- ATYR 6
- Target Price
- PKE N/A
- ATYR $20.20
- AVG Volume (30 Days)
- PKE 89.1K
- ATYR 3.9M
- Earning Date
- PKE 07-15-2025
- ATYR 08-12-2025
- Dividend Yield
- PKE 2.88%
- ATYR N/A
- EPS Growth
- PKE 4.18
- ATYR N/A
- EPS
- PKE 0.34
- ATYR N/A
- Revenue
- PKE $63,456,000.00
- ATYR N/A
- Revenue This Year
- PKE N/A
- ATYR $551.06
- Revenue Next Year
- PKE N/A
- ATYR $1,874.58
- P/E Ratio
- PKE $44.72
- ATYR N/A
- Revenue Growth
- PKE 16.60
- ATYR N/A
- 52 Week Low
- PKE $11.96
- ATYR $1.58
- 52 Week High
- PKE $17.71
- ATYR $5.98
- Technical
- Relative Strength Index (RSI)
- PKE 66.21
- ATYR 64.80
- Support Level
- PKE $15.00
- ATYR $5.19
- Resistance Level
- PKE $16.12
- ATYR $5.59
- Average True Range (ATR)
- PKE 0.46
- ATYR 0.37
- MACD
- PKE 0.08
- ATYR 0.00
- Stochastic Oscillator
- PKE 83.04
- ATYR 95.10
About PKE Park Aerospace Corp.
Park Aerospace Corp designs develop and manufactures engineered, advanced composite materials and composite structures and assemblies and low-volume tooling for the aerospace markets and prototype tooling for such structures and assemblies. Geographically, the company derives a majority of revenue from North America and also has a presence in a company operates its business in Asia and Europe. It offers advanced composite Prepregs for Aircraft Structures and Interiors, Sigma Strut and Alpha Strut.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.